CECCHI, FRANCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.430
EU - Europa 6.097
AS - Asia 3.486
SA - Sud America 580
Continente sconosciuto - Info sul continente non disponibili 100
AF - Africa 95
OC - Oceania 53
Totale 18.841
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.247
RU - Federazione Russa 1.634
PL - Polonia 1.565
IT - Italia 1.136
SG - Singapore 871
CN - Cina 832
HK - Hong Kong 515
BR - Brasile 464
VN - Vietnam 464
IE - Irlanda 437
SE - Svezia 367
KR - Corea 299
DE - Germania 223
FI - Finlandia 170
UA - Ucraina 151
FR - Francia 149
GB - Regno Unito 145
IN - India 127
CA - Canada 120
JO - Giordania 91
BD - Bangladesh 78
ID - Indonesia 56
AU - Australia 53
AR - Argentina 44
ES - Italia 39
JP - Giappone 38
MX - Messico 31
NL - Olanda 31
MA - Marocco 27
IQ - Iraq 22
TR - Turchia 20
EC - Ecuador 14
PY - Paraguay 14
CO - Colombia 13
PK - Pakistan 13
RO - Romania 12
VE - Venezuela 12
CI - Costa d'Avorio 11
ZA - Sudafrica 11
BE - Belgio 9
DZ - Algeria 9
TN - Tunisia 9
HN - Honduras 8
SC - Seychelles 8
AE - Emirati Arabi Uniti 7
IL - Israele 7
PH - Filippine 7
AT - Austria 6
CH - Svizzera 6
CL - Cile 6
KE - Kenya 6
PE - Perù 6
EG - Egitto 5
IR - Iran 5
UZ - Uzbekistan 5
DO - Repubblica Dominicana 4
NG - Nigeria 4
PR - Porto Rico 4
SA - Arabia Saudita 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
BW - Botswana 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
LT - Lituania 3
NP - Nepal 3
PS - Palestinian Territory 3
SY - Repubblica araba siriana 3
AZ - Azerbaigian 2
BO - Bolivia 2
CY - Cipro 2
DK - Danimarca 2
EU - Europa 2
GT - Guatemala 2
JM - Giamaica 2
KZ - Kazakistan 2
MY - Malesia 2
NO - Norvegia 2
PT - Portogallo 2
RS - Serbia 2
TW - Taiwan 2
AM - Armenia 1
BB - Barbados 1
BS - Bahamas 1
GR - Grecia 1
GY - Guiana 1
HU - Ungheria 1
KW - Kuwait 1
LB - Libano 1
LK - Sri Lanka 1
MN - Mongolia 1
MQ - Martinica 1
MU - Mauritius 1
NI - Nicaragua 1
OM - Oman 1
SI - Slovenia 1
SN - Senegal 1
VG - Isole Vergini Britanniche 1
Totale 18.743
Salva come PNG Salva come JPEG
Città #
Warsaw 1.562
Santa Clara 1.504
Ashburn 880
Fairfield 836
Singapore 604
Dublin 436
Hong Kong 418
Seattle 366
Woodbridge 361
Cambridge 335
Chandler 320
Seoul 293
Houston 292
Wilmington 267
Beijing 258
San Jose 252
Jacksonville 247
Milan 194
Los Angeles 145
Ho Chi Minh City 133
Rome 130
Ann Arbor 127
Hefei 126
Council Bluffs 116
Princeton 103
Lawrence 100
Buffalo 98
The Dalles 97
Altamura 95
Lauterbourg 93
Florence 91
Hanoi 88
Mumbai 86
Boston 84
Helsinki 75
Dallas 68
Moscow 68
Munich 55
New York 51
Dong Ket 48
Boardman 46
São Paulo 45
San Diego 42
Medford 40
Jakarta 39
Melbourne 39
Tokyo 33
Naples 32
Turku 32
Phoenix 30
Shanghai 30
Bologna 29
Redondo Beach 27
Toronto 26
Turin 25
Clifton 23
Norwalk 22
Da Nang 21
Montreal 21
Frankfurt am Main 20
Kent 18
Ottawa 18
Paris 18
Barcelona 17
Orem 17
Figino 16
London 15
Rio de Janeiro 14
Casablanca 13
Guangzhou 13
Haiphong 13
Nuremberg 13
Belo Horizonte 12
Brasília 12
Chicago 12
Long Branch 12
West Jordan 12
Abidjan 11
Catania 11
Miano 11
Palermo 11
Amman 10
Asunción 10
Atlanta 10
Brescia 10
Columbus 10
Madrid 10
Springfield 10
Thái Bình 10
Venice 10
Buenos Aires 9
Chennai 9
Genoa 9
Lappeenranta 9
San Francisco 9
Andover 8
Biên Hòa 8
Brussels 8
Frankfurt Am Main 8
Hillsboro 8
Totale 12.588
Salva come PNG Salva come JPEG
Nome #
The familial hypertrophic cardiomyopathy-associated myosin mutation R403Q accelerates tension generation and relaxation of human cardiac myofibrils 354
Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations. 350
Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy 332
Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy. 319
Relationship between atrial fibrillation and blunted hyperemic myocardial blood flow in patients with hypertrophic cardiomyopathy. 313
Clinical Features and Outcome of Hypertrophic Cardiomyopathy Associated With Triple Sarcomere Protein Gene Mutations 308
Significance of sarcomere gene mutations analysis in the end-stage phase of hypertrophic cardiomyopathy 300
Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy 298
β Blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy 290
Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center 274
Hemodynamic progression and outcome of asymptomatic aortic stenosis in primary care 252
International external validation study of the 2014 European society of cardiology guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM) 243
Myocardial bridging and sudden death in hypertrophic cardiomyopathy: Salome drops another veil 240
Myocardial blood flow and left ventricular functional reserve in hypertrophic cardiomyopathy: a 13NH3 gated PET study 235
Echocardiography in patients with hypertrophic cardiomyopathy: Usefulness of old and new techniques in the diagnosis and pathophysiological assessment 229
Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy 227
Genotype and lifetime burden of disease in hypertrophic cardiomyopathy insights from the sarcomeric human cardiomyopathy registry (SHaRe) 224
Malattia di Anderson-Fabry 224
An Investigation of the Molecular Mechanism of Double cMyBP-C Mutation in a Patient with End-Stage Hypertrophic Cardiomyopathy 224
CHARACTERISTICS OF MYOCARDIAL HYPERTROPHY IN FRIEDREICH'S ATAXIA. CLINICO-INSTRUMENTAL STUDY IN 10 PATIENTS AND REVIEW OF THE LITERATURE 223
Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events 223
Hypertrophic cardiomyopathy: prevalence of disease-specific red flags 221
Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy 219
Molecular Modeling of Disease Causing Mutations in Domain C1 of cMyBP-C 217
Prevalence and clinical significance of acquired left coronary artery fistulas after surgical myectomy in patients with hypertrophic cardiomyopathy 216
Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy 216
Beta-Blockers for Prevention of Exercise-induced Left Ventricular Outflow Obstruction in Patients with Hypertrophic Cardiomyopathy 212
Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives 211
MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol 207
Intraoperative diagnosis of Anderson-Fabry disease in patients with obstructive hypertrophic cardiomyopathy undergoing surgical myectomy 204
Impact of Genotype on the Occurrence of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy. 199
Usefulness of Electrocardiographic Patterns at Presentation to Predict Long-term Risk of Cardiac Death in Patients With Hypertrophic Cardiomyopathy 193
An expert consensus document on the management of cardiovascular manifestations of Fabry disease 190
Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy 190
Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions 189
European cardiomyopathy pilot registry: EURObservational research programme of the European society of cardiology 189
Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy 186
Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease. 186
Cardiovascular screening in low-income settings using a novel 4-lead smartphone-based electrocardiograph (D-Heart®) 183
Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. 182
Prognostic Value of N-Terminal Pro-Brain Natriuretic Peptide in Outpatients With Hypertrophic Cardiomyopathy. 182
Cardiomiopatie, Miocarditi e Pericarditi 181
HYPERTROPHIC CARDIOMYOPATHY 177
ARRHYTHMIAS ASSOCIATED WITH HYPERTROPHIC CARDIOMYOPATHY 177
Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy 173
Pattern and degree of left ventricular remodeling following a tailored surgical approach for hypertrophic obstructive cardiomyopathy 172
Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. 170
Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: Impact of age, atrial remodelling, and disease progression 170
CLINICAL PROFILE OF STROKE IN 900 PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 169
Multidisciplinary evaluation and management of obstructive hypertrophic cardiomyopathy in 2020: Towards the HCM Heart Team 169
Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy 167
The Case for Myocardial Ischemia in Hypertrophic Cardiomyopathy 165
RELEVANCE OF CORONARY MICROVASCULAR FLOW IMPAIRMENT TO LONG TERM REMODELING AND SYSTOLIC DYSFUNCTION IN HYPERTROPHIC CARDIOMYOPATHY 164
Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy 164
Histopathological comparison of intramural coronary artery remodeling and myocardial fibrosis in obstructive versus end-stage hypertrophic cardiomyopathy 164
Developmental origins of hypertrophic cardiomyopathy phenotypes: a unifying hypothesis. 162
Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis 161
Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy 158
Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal 155
Age-dependent diagnostic yield of echocardiography as a second-line diagnostic investigation in athletes with abnormalities at preparticipation screening 155
Echocardiographic features of right ventricular infarction. 153
Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. 152
Septal Ablation Versus Surgical Myomectomy for Hypertrophic Obstructive Cardiomyopathy 151
Prevalence and clinical profile of troponin T mutations among patients with hypertrophic cardiomyopathy in Tuscany 150
RISK OF ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY ASSESSED BY SIGNAL AVERAGED P WAVE DURATION 147
'End-stage' hypertrophic cardiomyopathy: from mystery to model 147
THE ITALIAN REGISTRY FOR HYPERTROPHIC CARDIOMYOPATHY: A NATIONWIDE SURVEY 146
IMPACT OF ATRIAL FIBRILLATION ON THE CLINICAL COURSE OF HYPERTROPHIC CARDIOMYOPATHY 146
TRANSIENT ASYMMETRIC VENTRICULAR SEPTAL HYPERTROPHY IN THE NEWBORN UNASSOCIATED WITH MATERNAL DIABETES 146
Stage-specific therapy for hypertrophic cardiomyopathy 146
MAXIMUM LEFT VENTRICULAR THICKNESS AND RISK OF SUDDEN DEATH IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 143
Right ventricular infarction: clinical, hemodynamic, mono- and two-dimensional echocardiographic features. 142
Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy 142
Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy 141
Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy 141
Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy 141
EPIDEMIOLOGY OF HYPERTROPHIC CARDIOMYOPATHY-RELATED DEATH: REVISITED IN A LARGE NON- REFERRAL-BASED PATIENT POPULATION 140
Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: Long-term results and clinical outcomes 139
Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy 137
Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy 134
Pathophysiology and Clinical Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy 131
HYPERTROPHIC CARDIOMYOPATHY IN TUSCANY: CLINICAL COURSE AND OUTCOME IN AN UNSELECTED REGIONAL POPULATION 130
PROGNOSTIC VALUE OF NON-SUSTAINED VENTRICULAR TACHYCARDIA AND THE POTENTIAL ROLE OF AMIODARONE TREATMENT IN HYPERTROPHIC CARDIOMIYOPATHY: ASSESSMENT IN AN UNSELECTED NON-REFERRAL BASEDE PATIENT POPULATION 128
CARDIOMIOPATIA IPERTROFICA 127
CLINICAL UTILITY AND SAFETY OF EXERCISE TESTING IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 125
Syncope in hypertrophic cardiomyopathy (part II): An expert consensus statement on the diagnosis and management 124
Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy 124
Prognostic significance of left atrial size in patients with hypertrophic cardiomyopathy (from the Italian Registry for Hypertrophic Cardiomyopathy) 123
THE NEED FOR EUROPEAN REGISTRIES IN INHERITED CARDIOMYOPATHIES 122
Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. 119
Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanism and clinical consequences 116
Other Modes of Disability or Death Including Stroke, and Treatment Strategies, in Hypertrophic Cardiomyopathy 115
EFFECT OF VERAPAMIL ON ABSOLUTE MYOCARDIAL BLOOD FLOW IN HYPERTROPHIC CARDIOMYOPATHY 114
Midventricular Obstruction and Clinical Decision-Making in Obstructive Hypertrophic Cardiomyopathy 114
A molecular screening strategy based on beta-myosin heavy chain, cardiac myosin binding protein C and troponin T genes in Italian patients with hypertrophic cardiomyopathy 112
CLINICAL COURSE OF HYPERTROPHIC CARDIOMYOPATHY IN A NON SELECTED POPULATION. EXPERIENCE OF THE ITALIAN MULTICENTER CARDIOMYOPATHY STUDY 109
RISK FACTORS AND STRATIFICATION FOR SUDDEN CARDIAC DEATH IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY 108
Layman electrocardiographic screening using smartphone-based multiple‑lead ECG device in school children 106
NEW CONCEPTS IN HYPERTROPHIC CARDIOMYOPATHIES 105
LONG-TERM OUTCOME OF PATIENTS WITH HYPERTROPHIC CARIOMYOPATHY SUCCESSFULLY RESUSCITATED AFTER CARDIAC ARREST 104
Totale 18.087
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.090
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.090
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022691 0 33 66 28 29 43 29 46 46 36 151 184
2022/20231.694 169 272 89 95 131 315 245 69 220 14 61 14
2023/2024590 23 72 118 36 38 78 18 109 15 32 20 31
2024/20254.453 165 481 267 680 1.294 561 63 305 198 132 168 139
2025/20265.789 478 760 436 719 572 221 609 312 359 323 201 799
2026/2027310 304 6 0 0 0 0 0 0 0 0 0 0
Totale 18.841